Biopharma | November 14, 2025
Transition Bio and Voyager Therapeutics forge strategic collaboration to target ALS, FTD
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
Funding to support Phase 2b trial with MRM Health’s lead program MH002 in ulcerative colitis and advance two additional programs to IND approval
Subscribe To Our Newsletter & Stay Updated
